<MedlineCitation Status="Completed">
<MedlineID>10011779</MedlineID>
<PMID>421088</PMID>
<DateCreated>
<Year>1979</Year>
<Month>05</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>05</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0007-1447</ISSN>
<JournalIssue>
<Volume>1</Volume>
<Issue>6159</Issue>
<PubDate>
<Year>1979</Year>
<Month>Feb</Month>
<Day>3</Day>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Comparison of intravenous and oral high-dose methotrexate in treatment of solid tumours.</ArticleTitle>
<Pagination>
<MedlinePgn>298-300</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>An outpatient regimen of oral high-dose methotrexate was studied in 14 patients with solid tumours over 12 months. Detailed pharmacokinetic analysis in five patients showed high oral bioavailability (mean +/- SE of mean 87.6 +/- 1.5%), indicating that with this regimen oral methotrexate was well absorbed and the first-pass effect low. Oral administration resulted in peak plasma methotrexate concentrations of 8.4 +/- 0.5 mumol/l (382 +/- 23 microgram/100 ml) and was almost as effective as intravenous administration, which achieved peak concentrations of 9.9 +/- 0.4 mumol/l (450 +/- 18 microgram/100 ml). In all 14 patients the clinical response to oral treatment was comparable to that reported to intravenous administration of high-dose methotrexate used in combination with other cytotoxic drugs. The disease-free interval in cases of adult sarcoma was 7.4 +/- 1.3 months and the relapse rate 29%. Out of four patients with small-cell carcinoma, two showed an objective response to oral treatment. We suggest that oral high-dose methotrexate given in divided doses is a rational alternative to expensive intravenous high-dose methotrexate regimens, but further clinical evaluation is necessary.</AbstractText>
</Abstract>
<AuthorList>
<Author>
<LastName>Christophidis</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author>
<LastName>Vajda</LastName>
<ForeName>F J</ForeName>
<Initials>FJ</Initials>
</Author>
<Author>
<LastName>Lucas</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Author>
<Author>
<LastName>Moon</LastName>
<ForeName>W J</ForeName>
<Initials>WJ</Initials>
</Author>
<Author>
<LastName>Louis</LastName>
<ForeName>W J</ForeName>
<Initials>WJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>ENGLAND</Country>
<MedlineTA>Br Med J</MedlineTA>
<NlmUniqueID>0372673</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>59-05-2</RegistryNumber>
<NameOfSubstance>Methotrexate</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Administration, Oral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Biological Availability</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Comparative Study</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Half-Life</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Human</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Injections, Intravenous</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Methotrexate</DescriptorName>
<QualifierName MajorTopicYN="Y">administration &#38; dosage</QualifierName>
<QualifierName>blood</QualifierName>
<QualifierName>therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Middle Age</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
